-
Spero Therapeutics NASDAQ:SPRO Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Location: 675 Massachusetts Ave Ste 14, Massachusetts, 02139-3309, US | Website: sperotherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
15.46M
Cash
63.53M
Avg Qtr Burn
-3.596M
Short % of Float
1.01%
Insider Ownership
20.38%
Institutional Own.
26.11%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tebipenem HBr (previously SPR994): oral carbapenem Details Bacterial infection, Urinary tract infection | Phase 3 Data readout | |
SPR206 Details Lung disease, Bacterial infection | Phase 2 Initiation | |
SPR720 Details Lung disease, Bacterial infection | Phase 2a Data readout |